Search

Your search keyword '"Zehnter E"' showing total 221 results

Search Constraints

Start Over You searched for: Author "Zehnter E" Remove constraint Author: "Zehnter E"
221 results on '"Zehnter E"'

Search Results

1. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients

2. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure

3. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections

4. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

5. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections

6. Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naïve patients: Final results from startverso1, a randomised, double-blind, placebo-controlled phase III trial

7. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections

11. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

12. Low frequency of drug-drug interactions (DDIs) with the novel all oral antivirals elbasvir (EBV) and grazoprevir (GRZ) in patients with HCV genotype 1 infection in German real-world

13. Boceprevir triple therapy of chronic HCV genotype 1 (G1) infection in previously untreated patients: Efficacy, predictability of virologic response and safety in German real-life

16. Treatment of chronic HCV Genotype 1 infection with Boceprevir in German real-life:The impact of SVR on initially elevated and initially normal serum alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT) levels

17. Gender-dependent differences in the efficacy and safety of Boceprevir triple therapy in German real-life

18. Current evaluation of the patient with chronic HCV genotype 1 infection before antiviral treatment in German routine clinical practice

19. Boceprevir triple therapy of HCV genotype 1 (G1) infection in German real-life: comparable high SVR rates up to 87% in treatment-naïve and previously treated patients who achieve an early virologic response

20. Gender- and age-related co-morbidities of patients undergoing treatment of chronic HCV G1 infection in German real-life

21. Serum gamma-glutamyl transferase (GGT) levels within the normal range are associated with a high SVR rate of 85% in treatment-naive patients undergoing Boceprevir triple therapy for HCV genotype 1 (G1) infection in German real-world

23. Baseline predictors of an early virologic response (EVR) in previously untreated patients undergoing boceprevir (BOC) triple therapy for HCV genotype 1 infection in German real-life

24. Current clinical evaluation of the patient with HCV genotype 1 infection before antiviral treatment in German routine clinical practice

25. Treatment of previously untreated patients with chronic HCV genotype 1 infection with boceprevir in German real-life: high end of treatment response of 95% in patients with early virologic response

26. Baseline gamma-GT levels within the normal range predict high virologic response rates in treatment-naïve patients undergoing boceprevir triple therapy for HCV genotype 1 (G1) infection

27. Renal impairment under triple therapy with boceprevir in German real-life: evidence for a pivotal role for peginterferon/ribavirin backbone, female gender and age elder than 50 years

28. Female gender, age elder than 50 years and a reduced glomerular filtration rate (eGFR) at baseline strongly predict the frequency of anemia in patients undergoing boceprevir triple therapy in German real-life

30. P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION

31. P1118 NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS

32. P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES

33. P1109 OVERTREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 2/3 WITH LOW BASELINE VIRAL LOAD AND RVR: EXPERIENCES IN A REAL WORLD SETTING

34. P1131 SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS

35. P1132 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION WITH PRIOR RELAPSE

36. P1147 OUTCOMES AND COSTS OF TREATING HEPATITIS C WITH PROTEASE INHIBITORS: RESULTS FROM A MULTI-CENTRE STUDY

37. Epidemiology, Treatment Outcomes and Costs of Treating Hepatitis C in Routine Care – Results from a Large Multicenter Trial

38. Leukocytes decline > 2500/µl during Peginterferon Alfa-2B (PEG-2B)/Ribavirin (RBV) treatment predicts favorable SVR rates in difficult-to-treat patients with HCV Genotype 1 (G1) infection in real-life

39. Treatment of chronic hepatitis C by Pegylated Interferon Alfa-2b (Peg2b) and Ribavirin (RBV): Age-and gender dependent frequency of hematological alterations in a German real-life cohort

40. Prädiktive Baseline Faktoren bei Patienten mit Zirrhose für den Therapieerfolg einer dualen Therapie mit Peginterferon alfa-2a (PEG) plus Ribavirin (RBV), was zählt?

41. Epidemiologie, Behandlungsergebnisse und Kosten der Behandlung chronischer HCV-Patienten in Deutschland - Ergebnisse einer großen Multicenter Studie

42. Thyroid dysfunction induced by peginterferon alfa-2b (Peg-2b)/Ribavirin (Rbv) is associated with higher SVR rates in patients with HCV Genotype 1 (G1) infection due to improved early virologic response at week 4 and week 12

43. Faldaprevir (FDV) plus pegyliertes Interferon alpha-2a und Ribavirin (PegIFN/RBV) bei bisher unbehandelten Patienten mit chronischer Hepatitis C vom Genotyp (GT)-1: Endergebnisse von STARTVerso1, einer randomisierten, plazebo-kontrollierten, Doppelblind-Phase III Studie

44. 1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL

45. 830 CHOLESTEROL LEVELS AND PRESENCE OF DIABETES PREDICT EARLY VIROLOGICAL RESPONSE TO TRIPLE THERAPY WITH TELAPREVIR, PEG-INTERFERON alfa-2a 180 μg AND RIBAVIRIN IN CHRONIC HEPATITIS C

46. 912 LEUKOCYTE DECLINE PREDICTS SUSTAINED VIROLOGIC RESPONSE IN PATIENTS UNDERGOING PEGINTERFERON alfa-2b/RIBAVIRIN TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION

47. Thyroid dysfunction induced by Peginterferon alfa-2B (PEG-2B)/Ribavirin (RBV) is a favorable predictor of SVR in patients with HCV genotype 1 (G1), but not HCV genotype 2/3 (G2/3) infection

48. Age- and gender-related differences in SVR and relapse following treatment of HCV genotype 3 (G3) infection with Peginterferon alfa-2b (peg2b)/Ribavirin (RBV) in real-life

50. Sustained responders have lower rates of liver-related events and a better quality of life and productivity compared with non-responders/relapsers after antiviral treatment of chronic hepatitis C

Catalog

Books, media, physical & digital resources